Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,159,681 shares of the company's stock after selling 230,166 shares during the quarter. Assenagon Asset Management S.A. owned 0.10% of Teva Pharmaceutical Industries worth $25,559,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the company. Sanctuary Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after buying an additional 664 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company's stock valued at $2,025,000 after acquiring an additional 805 shares during the last quarter. DGS Capital Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 6.8% during the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after acquiring an additional 872 shares during the last quarter. Smithfield Trust Co increased its position in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Finally, Signaturefd LLC raised its stake in Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company's stock valued at $137,000 after purchasing an additional 1,094 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Trading Up 1.3 %

Shares of NYSE TEVA traded up $0.29 during trading on Friday, hitting $21.97. 8,962,859 shares of the company traded hands, compared to its average volume of 9,541,109. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The firm has a market capitalization of $24.89 billion, a P/E ratio of -25.84, a P/E/G ratio of 1.06 and a beta of 0.73. The company has a 50-day moving average price of $19.24 and a 200-day moving average price of $18.20. Teva Pharmaceutical Industries Limited has a 1 year low of $10.86 and a 1 year high of $22.80.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on TEVA shares. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 18th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday. Finally, JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $22.13.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.